!
Smallcaps Daily
# The Biotech Stock Soaring 63% on Unprecedented Cancer Trial Results – Meet Janux Therapeutics
Smallcaps Daily Updates
2 months ago
!!
Janux Therapeutics (NASDAQ:JANX) has been making waves in the biotech space, and recent developments underscore its potential to revolutionize prostate cancer treatment. On December 3, 2024, the company announced groundbreaking results for its lead drug candidate, JANX007, a tumor-activated T-cell engager targeting advanced-stage prostate cancer. In a Phase I clinical trial, 100% of heavily pretreated patients achieved a reduction in prostate-specific antigen (PSA) levels by at least 50%, with 63% reaching a PSA90 (90% reduction). This transformative data has propelled the stock by 63%, reinforcing confidence in Janux’s innovative TRACTr platform. Beyond the trial results, Janux’s solid financial footing, with $658 million in cash, ensures the continuation of its promising pipeline, including the expansion of JANX007 into second- and third-line treatments and further clinical developments for JANX008 targeting EGFR-positive tumors. These developments have made Janux made it a key player addressing unmet needs in prostate cancer, offering both safety and efficacy in a highly competitive market.
### **JANX007’s Unmatched Efficacy In Advanced Prostate Cancer**
JANX007 has demonstrated exceptional efficacy in treating metastatic castration-resistant prostate cancer (mCRPC), setting new benchmarks in the field. The drug’s novel mechanism uses tumor-activated T-cell engagers that activate in the tumor microenvironment, ensuring potent cancer cell targeting while minimizing off-target effects. The Phase I trial showed that all patients achieved PSA50, with 63% achieving PSA90, far surpassing competitors like Pluvicto and Amgen’s STEAP1 programs, which reached only 28% at PSA90. Moreover, JANX007’s durability has been impressive, with 75% of patients maintaining PSA50 for over 12 weeks and 50% maintaining PSA90. Unlike traditional therapies, the drug remains effective even against androgen receptor mutations, amplifications, and variants that commonly cause resistance. Janux’s innovative dosing regimens, including step-dose approaches, optimize the drug’s safety and efficacy. Compared to existing options, JANX007’s ability to deliver deep, rapid, and durable responses represents a potential paradigm shift in prostate cancer care, with applicability across earlier lines of therapy. This efficacy positions the drug not just as a treatment for late-stage patients but as a candidate for broader use in second- and first-line settings, making it a compelling choice for oncologists and a lucrative opportunity in a multibillion-dollar market.
### **Proven Safety Profile Enhancing Long-Term Use**
Safety is a cornerstone of JANX007’s clinical success. Unlike earlier-generation T-cell engagers that failed due to excessive toxicity, JANX007 leverages Janux’s TRACTr platform to minimize adverse events. The trial’s results highlighted a well-tolerated safety profile, with most cytokine release syndrome (CRS) events confined to Grade 1 or 2 during the first cycle and negligible occurrences in subsequent cycles. Importantly, the design of the drug ensures that the active T-cell engager remains concentrated in the tumor, reducing the risk of accumulation in healthy tissues. This precision allows for higher dosing levels (up to 12 mg in ongoing studies) without compromising patient safety, a feat unmatched by previous PSMA-targeting agents. Moreover, Janux’s proactive approach to CRS management, including optimized steroid use, has further reduced adverse effects while maintaining robust immune responses. These advancements highlight the company’s commitment to patient-centric innovation, making JANX007 a highly viable option for long-term treatment plans. By maintaining low systemic exposure to active engagers, Janux not only enhances the safety profile but also improves patient adherence and outcomes, addressing critical gaps in existing prostate cancer therapies.
### **Robust Financials & Expanding Pipeline**
Janux’s financial strength provides a solid foundation for its ambitious clinical programs. With $658 million in cash and equivalents, the company is well-positioned to advance JANX007 through Phase Ib expansion trials and initiate Phase II/III studies without the need for external funding. This financial cushion also enables the development of its next-generation TRACTr candidates, including JANX008 for EGFR-positive cancers and additional programs entering clinical evaluation in 2025. The pipeline diversification reduces reliance on a single asset, broadening its market potential. Beyond its financial metrics, Janux’s strategic focus on pre-Pluvicto-treated patients in second- and third-line settings highlights its market-savvy approach, targeting large unmet needs in a growing oncology segment. Analysts have already raised their peak U.S. sales estimates for JANX007 to $3 billion, citing its strong clinical profile and scalability. The company’s ability to quickly enroll patients and generate actionable data underscores its operational efficiency, further cementing investor confidence. Janux’s progress, coupled with its well-defined path to regulatory approval, underscores its potential to deliver significant value to both patients and shareholders.
### **Conclusion: A Possible Acquisition Target?**
*Source: Yahoo Finance*
We can see the massive 63% spike in Janux Therapeutics’ stock price in a single session after the major update. The company is setting a new standard in prostate cancer treatment with its innovative TRACTr platform and groundbreaking results from the JANX007 program. While the stock’s rapid ascent reflects optimism, potential investors should weigh the risks, including regulatory hurdles and competitive pressures, alongside the company’s remarkable achievements. With its compelling safety and efficacy data, robust pipeline, and financial strength, Janux Therapeutics presents a unique opportunity in the evolving oncology landscape and we believe that the company could prove to be a solid acquisition target for large pharma and biotech players as well.
Categories: , , 
## Smallcaps Daily
Friday, January 24 2025
Breaking News
* Facebook
* Telegram
* Log In
* Sidebar
* Menu
* Search for
# Women and Black adults waited longer in ER for chest pain evaluation
Send an email
May 4, 2022 377  6 minutes read
[ad\_1]
Research Highlights:
* According to national survey data on emergency room (ER) treatment, women (ages 18 to 55) who reported chest pain, the most common symptom of a heart attack in adults of all ages, received a slower and less thorough initial evaluations than men in the same age group.
* In this analysis, patients noted as people of color waited 10-15 minutes longer to receive care for chest pain in the ER compared to white adults.
* People of color received similar evaluation and treatment in the ER for chest pain, except for longer wait times, compared to white patients.
**Embargoed until 4 a.m. CT/5 a.m. ET Wednesday, May 4, 2022**
() – May 04, 2022 – DALLAS – Women (ages 18 to 55) waited longer to be evaluated for  in the emergency room (ER) and received a less thorough evaluation for a possible  than men in the same age range. Similarly, people of color (89% non-Hispanic Black adults in this study) with chest pain waited longer before being seen in the ER than white adults with chest pain, according to new research published today in the , an open access, peer-reviewed journal of the American Heart Association.
According to a 2021 American College of Cardiology/American Heart Association guideline, chest pain accounts for more than 6.5 million ER visits annually in the United States, plus nearly 4 million outpatient visits. The  introduced new guidelines dedicated solely to chest pain to help doctors identify people who are highest risk for heart attack and to help reduce unnecessary testing in those who aren’t. Chest pain is the most frequent symptom of heart attack for both men and women, however, women may be more likely to also exhibit accompanying symptoms such as nausea and shortness of breath.
“Chest pain is the most common symptom of heart attack in adults of all ages. Despite a decline in the number of overall heart attacks, this number is rising among young adults. Young women and young Black adults have poorer outcomes after a heart attack compared to men and white adults” said Darcy Banco, M.D., M.P.H., lead author of the study and chief resident for safety and quality in the department of medicine at the NYU Grossman School of Medicine in New York City. “Whether or not the differences in chest pain evaluation directly translate into differences in outcomes, they represent a difference in the care individuals receive based on their race or sex, and that is important for us to know.”
To learn more about the initial evaluation in the ER of younger people with chest pain, researchers analyzed a nationally representative sample of more than 4,000 patient records, representing more than 29 million ER visits among adults aged 18-55 years old seen in an ER for chest pain between 2014 and 2018. The data was collected by the National Hospital Ambulatory Medical Care Survey, a routine and standardized survey of emergency departments across the U.S. focused on understanding why people go to the ER and the care received in the ER.
Records were included in the analysis if any of these were listed as reasons for the ER visit: chest pain; chest pain and related symptoms; chest discomfort, pressure or tightness; burning sensation in the chest; or heart pain. Race was also listed in the records. For this analysis, participants were divided into two groups: 1) white or 2) people of color (any race or ethnicity other than white), of which 89% were noted as non-Hispanic Black. Analysis by other race or ethnicity categories was not possible due to the small number of people in the racial and ethnic groups other than non-Hispanic Black.
The researchers found:
* Women waited almost 11 minutes longer to be seen by a health care professional compared to men (48 minutes vs. 37 minutes, respectively).
* Women were less likely to have an  (measures electrical activity of the heart) than men (74.2% vs. 78.8%, respectively).
* Women were less likely to be admitted to the hospital or an observation unit than men (12.4% vs. 17.9%, respectively).
* Compared with white women, women of any other race or ethnicity waited 15 minutes longer for their initial evaluation (58 minutes vs. 43 minutes, respectively), while men of any other race or ethnicity waited 10 minutes longer than white men (44 minutes vs. 34 minutes, respectively).
* After adjusting for age and other factors, researchers noted women and people of color waited longer for initial evaluation, but there were no significant sex or racial differences in the odds of receiving an electrocardiogram or cardiac enzyme testing.
* Additionally, women were less likely to be admitted to the hospital than men.
“We anticipated we might see differences later on in care (such as calling in a specialist or admitting someone to the hospital), rather than in the early evaluation (such as time to first physician contact and electrocardiogram ordering),” Banco said. “We were also surprised to find differences in wait time by race, as the rate of heart attack among Black adults versus white adults is similar.”
Harmony R. Reynolds, M.D., senior author of the study and director of the Sarah Ross Soter Center for Women’s Cardiovascular Research and associate professor of medicine at the NYU Grossman School of Medicine, noted, “Minutes count when someone has a heart attack. Calling an ambulance is also helpful because emergency medical technicians can treat chest pain and heart attack right away. People who arrive to the ER by ambulance often receive urgent care and attention sooner compared to people who arrive to the ER on their own.”
The study reported several limitations: most adults with chest pain who are seen in the ER do not have a heart attack, and while large, this database did not include enough people in the targeted age range (18-55 years) diagnosed with heart attack to allow examination of differences in ER treatment among only those people who had a heart attack; and it was not possible to review the details of each encounter to understand the reasons for delays as there was not information available on evaluations or treatments done by emergency medical services prior to arrival at the ER, specific reasons for any delays, or the results of cardiac testing.
Additional research is needed to discover the underlying reasons for these delays and to find opportunities to improve care, researchers said.
“The findings raise many questions for future research. Do differences in wait time vary with location? Are the differences related to variation in hospital care quality, or are these differences applicable to all ERs? Lastly, do differences in wait time translate to differences in outcomes,” Banco said.
Co-authors are Jerway Chang, M.D.; Nina Talmor, M.D.; Priya Wadhera, M.D.; Amrita Mukhopadhyay, M.D.; Xinlin Lu, M.S.; Siyuan Dong, M.S.; Yukun Lu, M.S.; Rebecca A. Betensky, Ph.D.; Saul Blecker, M.D.; and Basmah Safdar, M.D.
The National Hospital Ambulatory Health Care Survey-Emergency Room registry is funded by the U.S. Centers for Disease Control and Prevention.
Studies published in the American Heart Association’s scientific journals are peer-reviewed. The statements and conclusions in each manuscript are solely those of the study authors and do not necessarily reflect the Association’s policy or position. The Association makes no representation or guarantee as to their accuracy or reliability. The Association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific Association programs and events. The Association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and biotech companies, device manufacturers and health insurance providers and the Association’s overall financial information are available .
**Additional Resources:**
**About the American Heart Association**
The American Heart Association is a relentless force for a world of longer, healthier lives. We are dedicated to ensuring equitable health in all communities. Through collaboration with numerous organizations, and powered by millions of volunteers, we fund innovative research, advocate for the public’s health and share lifesaving resources. The Dallas-based organization has been a leading source of health information for nearly a century. Connect with us on , ,  or by calling .
**###**
**For Media Inquiries and AHA/ASA Expert Perspective:** 
Karen Astle: ; 
For Public Inquiries:  ()
 and 
[ad\_2]
 Tags       
Show More
 Share
Share via Email
### Related Articles
### 
1 week ago
3 weeks ago
4 weeks ago
Check Also
Close
  4 weeks ago
Newsletter
##### Free Alerts from Smallcaps Daily.
### Subscribe to our mailing list to get the newest Smallcap alerts as soon as we get them!
###### We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on stock market & finance related, articles, news and trade alerts.
Leave this field empty if you're human: 
  1 week ago
  3 weeks ago
  December 24, 2024
  September 12, 2023
  September 21, 2023
  September 1, 2023
  December 14, 2020
  March 10, 2022
Recent News
### Trending Tickers
WISH
$9.18
27.72%
Leave this field empty if you're human:
* About
SmallCapsDaily.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, in-depth broadcasts on Stock News, Market Analysis and Company Interviews.
SmallCapsDaily.com also provides financial news PR marketing and advertising for third parties for disseminating news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.
© Copyright 2025, All Rights Reserved  |   
Viber
Search for:
Popular Posts
  November 24, 2024
  November 25, 2024
Recent Comments
Log In
 Remember me